Related Experiment Videos
Limbal stem cell transplantation in chronic inflammatory eye disease
C Michael Samson1, Constance Nduaguba, Stefanos Baltatzis
1Ocular Immunology and Uveitis Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.
Objective:
The goal of this study was to describe the outcome of limbal stem cell transplantation (LSCT) in patients with severe ocular surface disease caused by underlying chronic inflammatory eye disease.
Design:
Retrospective noncomparative case series.
Participants:
Nine patients with limbal stem cell deficiency caused by an underlying ocular inflammatory disease who underwent LSCT.
Methods:
The authors reviewed the records of 11 eyes of 9 patients with immunologically mediated ocular surface disease that underwent LSCT.
Main Outcome Measures:
The main outcome measures were reepithelialization of the corneal surface, restoration of corneal surface, and improvement in visual acuity.
Results:
A total of 11 eyes underwent either autologous (n = 1) or HLA-matched living related donor (n = 10) LSCT for ocular surface disease secondary to inflammatory disease. Reepithelialization of the corneal surface in the immediate postoperative period occurred in 10 eyes (91%) within an average of 10 days (range, 3-21 days). Long-term restoration of the corneal surface was achieved in six (55%) eyes. Visual acuity improved in six eyes (55%). Reasons for poor outcomes included microbial infection, limbal stem cell graft rejection, and corneal ulceration. No donor eyes had complications.
Conclusions:
Patients with underlying immunologically mediated diseases, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or ocular cicatricial pemphigoid, who undergo LSCT have lower success rates than do those patients with noninflammatory ocular surface diseases.